Telemedics
Prezzo: 72.91Società e modello di business
Telemedics (TMDX.US) operates in the healthcare sector, focusing on advanced telemedicine solutions. Its core products include remote patient monitoring systems and digital health platforms that facilitate virtual consultations and data analytics. The company generates revenue primarily through subscription services and software licensing, catering to healthcare providers and patients.
Profilo di investimento
The investment profile of Telemedics is more aligned with balanced investors, given its moderate growth potential and current market position. The absence of dividends and the high risk associated with its operations suggest a cautious approach. The stock may appeal to those looking for a mix of growth and stability over a medium to long-term horizon.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- 5.03 OK
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- 8.2% ↑
- Sorpresa EPS
- -51.6% peggio del previsto
- Volatilità 20g
- 2.8% stabile
Impatto della previsione
neutraleTraccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-06-03 02:54 | Mantieni | Vendi | Weak fundamentals and negative momentum indicate high risk. |
| 2026-05-08 15:07 | — | Mantieni | Weak momentum and high risk overshadow potential growth. |
| 2026-05-08 05:33 | Mantieni | Mantieni | Компания демонстрирует значительное снижение цен на акции за последние месяцы, что указывает на высокие риски. Несмотря на положительные показатели EPS и рост выручки, текущая динамика цен не внушает доверия. |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-05-26 10:50 | Stifel Nicolaus | Target abbassato | 85 → 75 | 68.935 |
| 2026-05-06 13:42 | Needham | Target abbassato | 174 → 142 | 73.8351 |
| 2026-05-06 11:46 | Canaccord Genuity | Target abbassato | 152 → 124 | 94.93 |
Ancora nulla